Loading
A phase 3 trial of serplulimab, nab-paclitaxel, carboplatin, doxorubicin and other drugs in triple-negative breast cancer, run by Shanghai Henlius Biotech, not yet recruiting.
to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC) is a phase 3, randomised interventional study registered as NCT04301739 by Shanghai Henlius Biotech, with a registry enrolment figure of 522 participants, started 2020-04-17 and due to reach its primary completion in 2022-09-07. Interventions recorded: HLX10; nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide; Placebo. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Subjects histologically diagnosed with previously untreated TNBC (lack of human epidermal growth factor receptor-2 \[HER2\], estrogen receptor \[ER\], progesterone receptor expression as determined by the study site)". No results are recorded here; the registry entry is the source.
Shares Epirubicin, Nab-paclitaxel, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Epirubicin, Cyclophosphamide, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Nab-paclitaxel, Cyclophosphamide, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Epirubicin, Cyclophosphamide, Doxorubicin, Early triple-negative breast cancer and the tag tnbc-deep-dive.
Shares Epirubicin, Cyclophosphamide, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Serplulimab, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents and the tag tnbc-deep-dive.
Shares Cyclophosphamide, Doxorubicin, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Epirubicin, Cyclophosphamide, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.